Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy

Gironda, Daniel J.; Adams, Daniel L.; He, Jianzhong; Xu, Ting; Gao, Hui; Qiao, Yawei; Komaki, Ritsuko; Reuben, James M.; Liao, Zhongxing; Blum-Murphy, Mariela; Hofstetter, Wayne L.; Tang, Cha‐Mei; Lin, Steven H.

doi:10.1186/s12967-020-02563-x

Cited by 28 publications

(45 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most intriguing is the nature of these giant cells, which have been identified in patients with cancers but not in healthy donors [ 33 ]. They were given different names: circulating hybrid E/M cells, giant epithelioid cells, fusion-derived epithelial cancer cells, tumor-macrophage fusion cells (TMFs), macrophage-tumor cell fusion cells (MTFs), or cancer-associated macrophage-like (CAMLs) cells [ 22 , 30 , 32 , 33 , 34 , 35 , 36 ]. This shows that the origin of g - aCTCs is unclear.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients

Lopresti

Acquaviva

Boudin

et al. 2022

Cancers

View full text Add to dashboard Cite

Circulating tumor cells have a strong potential as a quasi-non-invasive tool for setting up a precision medicine strategy for cancer patients. Using a second-generation “filtration-based” technology to isolate CTCs, the Screencell™ technology (Sarcelles, France), we performed a large and simultaneous analysis of all atypical circulating tumor cells (aCTCs) isolated from the blood of metastatic breast cancer (mBC) patients. We correlated their presence with clinicopathological and survival data. We included 91 mBC patients from the PERMED-01 study. The median number of aCTCs was 8.3 per mL of blood. Three subsets of aCTCs, absent from controls, were observed in patients: single (s-aCTCs), circulating tumor micro-emboli (CTM), and giant-aCTCs (g-aCTCs). The presence of g-aCTCs was associated with shorter progression free survival and overall survival. This study highlights the heterogeneity of aCTCs in mBC patients both at the cytomorphological and molecular levels. In addition, it suggests the usefulness of the g-aCTC subset as a prognostic factor and a potential stratification tool to treat late-stage mBC patients and improve their chances of benefiting from early clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Other studies have identified these large cells as cells related to the macrophage lineage, describing them in a broad way as giant macrophages (CAMLs, MTF, or MFT) that contain phagocytosed epithelial debris [ 22 , 31 , 33 , 34 , 35 , 38 ]. These cells indeed express CD14 or CD11c, two markers of the macrophage/myeloid lineage.…”

Section: Discussionmentioning

confidence: 99%

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients

Lopresti

Acquaviva

Boudin

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Recently, a second type of tumor associated cell has been discovered, the cancer associated macrophage-like cell (CAML). This cell has been described as a pro-tumorigenic giant myeloid cell found in circulation, along with CTCs in several solid tumor cancers, including PC [6][7][8][9][10]. CAMLs have been shown to reliably predict progression and survival in PC, which may also be related to CTC intravasation into circulation [8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“…This cell has been described as a pro-tumorigenic giant myeloid cell found in circulation, along with CTCs in several solid tumor cancers, including PC [6][7][8][9][10]. CAMLs have been shown to reliably predict progression and survival in PC, which may also be related to CTC intravasation into circulation [8][9][10][11]. Another circulating tumor associated cell (TAC), that has been implicated in the progression of PC, is the epithelial-mesenchymal transition cell (EMT) [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

CXCR4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

The aggressive nature and metastatic potential of pancreatic cancer (PC) results in poor prognosis and high mortality. A better understanding of the underlying biology of PC and the ability of tumor cells to spread to distant sites is needed to advance the treatment of PC. The chemokine receptor CXCR4 has been heavily implicated in the spread and mobility of many solid cancers based on its role in cancer cell chemotaxis as well as increased metastatic potential. To better elucidate CXCR4’s role in the metastatic spread of PC, we examined its expression on various tumor associated cells (TACs) in the peripheral blood of PC patients, including circulating tumor cells (CTCs), epithelial to mesenchymal transition cells (EMTs), and cancer associated macrophage-like cells (CAMLs). In this pilot study, blood samples were procured from 30 PC patients prior to the start of therapeutic intent. CXCR4 expression was analyzed on TACs captured from the blood samples and evaluated in relation to cell migration as well as patient clinical outcomes. In total, CTCs, EMTs, and CAMLs were found in 27%, 60%, and 97% of PC patients, respectively. High CXCR4 expression in CTCs, CAMLs, and EMTs was found to significantly relate to their increased numbers in circulation. Further, higher expression of CXCR4 in CAMLs and EMTs was significantly related to faster progression and worse survival. These data suggest that CXCR4 expression in PC is strongly related to the intravasation and presence of TACs into circulation, as well as being a possible biomarker for aggressive metastatic disease.

show abstract

“…Thus far, the main treatment method for ESCC is a combined treatment of radiotherapy, chemotherapy, and surgery [ 3 ]. The emergence of drug resistance in molecular targeted therapy leads to poor clinical efficacy in patients with ESCC [ 4 , 5 , 6 , 7 ]. According to statistics, from 2010 to 2016, the 5‐year survival rate remains poor (20%) [ 1 ], and the mortality rate has remained high [ 8 , 9 , 10 ].…”

mentioning

confidence: 99%

Overexpression of cyclin‐dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance

Zhang

Chen

et al. 2021

FEBS Open Bio

View full text Add to dashboard Cite

Cyclin-dependent kinase 1 (CDK1) plays a significant role in certain malignancies. However, it remains unclear whether CDK1 plays a role in esophageal squamous cell carcinoma (ESCC). The aim of this study was to analyze the expression and clinical value of CDK1 in ESCC. CDK1 protein in 151 ESCC tissues and 138 normal esophageal tissues was detected by immunohistochemistry. RNA-seq of eight pairs of ESCC and adjacent esophageal specimens was performed to evaluate the levels of CDK1 mRNA. Microarray and external RNA-seq data from 664 cases of ESCC and 1733 cases of control tissues were used to verify the difference in CDK1 expression between the two groups. A comprehensive analysis of all data was performed to evaluate the difference in CDK1 between ESCC tissues and control tissues. Further, functional enrichment analyses were performed based on differentially expressed genes (DEGs) of ESCC and coexpressed genes (CEGs) of CDK1. In addition, a lncRNA-miRNA-CDK1 network was constructed. The expression of CDK1 protein was obviously increased in ESCC tissues (3.540 AE 2.923 vs. 1.040 AE 1.632, P < 0.001). RNA-seq indicated that the mRNA level of CDK1 was also highly expressed in ESCC tissues (5.261 AE 0.703 vs. 2.229 AE 1.161, P < 0.0001). Comprehensive analysis revealed consistent up-regulation of CDK1 (SMD = 1.41; 95% CI 1.00-1.83). Further, functional enrichment analyses revealed that the functions of these genes were mainly concentrated in the cell cycle. A triple regulatory network of PVT1-hsa-miR-145-5p/hsa-miR-30c-5p-CDK1 was constructed using in silico analysis. In summary, overexpression of CDK1 is closely related to ESCC tumorigenesis.Esophageal cancer is one of the most common malignant tumors in the world and is the seventh highest cause of cancer-related death [1]. There are approximately 19,260 new cases and 15,530 deaths each year [1]. Esophageal squamous cell carcinoma (ESCC) is the main subtype of esophageal cancer, accounting for 90% of all esophageal cancers [2]. Thus far, the main treatment method for ESCC is a combined treatment of radiotherapy, chemotherapy, and surgery [3]. The emergence of drug resistance in molecular targeted Abbreviations CDKs, cyclin-dependent kinases; CDK1, cyclin-dependent kinase 1; CEGs, co-expressed genes; DEGs, differentially expressed genes; ESCC, esophageal squamous cell carcinoma.

show abstract

Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy

Cited by 28 publications

References 29 publications

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients

CXCR4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer

Overexpression of cyclin‐dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance

Contact Info

Product

Resources

About